Reporting owner · CIK 0001982614

Jeggle Helmut Wolfgang

SEC Form 4 history across 1 companies, 5 transactions and 1 filings.

DIRBambusa Therapeutics, Inc.
Open-market transaction mix100% buys1 buys · 0 sales

Available history · Nov 02, 2026 – Nov 02, 2026

Filings1Form 4 records
Buying$6M1 purchases
Selling$00 sales
Net value$6MBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from available history.
Jeggle Helmut Wolfgang transactions · 20 per page
CompanyInsiderActivityDisclosed valueFiled (ET)
BBTXBambusa Therapeutics, Inc.
Jeggle Helmut WolfgangDIRC · unknownDerivative securitySEC filing ↗$0View disclosure →
BBTXBambusa Therapeutics, Inc.
Jeggle Helmut WolfgangDIRC · unknownDerivative securitySEC filing ↗$0View disclosure →
BBTXBambusa Therapeutics, Inc.
Jeggle Helmut WolfgangDIRC · unknownDerivative securitySEC filing ↗$0View disclosure →
BBTXBambusa Therapeutics, Inc.
Jeggle Helmut WolfgangDIRP · buySEC filing ↗$6.00MView disclosure →
BBTXBambusa Therapeutics, Inc.
Jeggle Helmut WolfgangDIRC · unknownSEC filing ↗UnknownView disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

buy at Bambusa Therapeutics, Inc. on Nov 02, 2026 valued at $6,000,000.

Review SEC filing
Latest buy

buy at Bambusa Therapeutics, Inc. on Nov 02, 2026 valued at $6,000,000.

Review SEC filing
Latest sale

No open-market insider sale is available.

Monthly open-market activity

Last 1 reported months · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
Nov 202610$6,000,000.00$0.00$6,000,000.00

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$6M
Median P/S size$6M
Direct0
Indirect5
Nov 02, 2026unknown

Associated companies

Companies in the disclosed reporting history

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

No purchases currently have the price observations needed for a 90-day return. This may reflect incomplete price coverage or purchases that have not reached the return window.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

2 observations · Nov 2, 2026 – Nov 2, 2026. Window ends at the latest available report, not today.

Selected observation · Nov 2, 20269,264,301 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Nov 2, 20268,889,301Nov 2, 2026View transaction
Nov 2, 20269,264,301Nov 2, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Jeggle Helmut Wolfgang Insider Activity FAQ

SEC Form 4 context

Who is Jeggle Helmut Wolfgang?

Jeggle Helmut Wolfgang is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001982614.

Which companies has Jeggle Helmut Wolfgang reported transactions for?

Bambusa Therapeutics, Inc.

When was Jeggle Helmut Wolfgang's latest insider buy?

buy at Bambusa Therapeutics, Inc. on Nov 02, 2026 valued at $6,000,000.

When was Jeggle Helmut Wolfgang's latest insider sale?

No open-market insider sale is available for this period.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.